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Objective To compare the effectiveness of melarsoprol and eflornithine in treating late-stage Gambian trypanosomiasis in the 
Republic of the Congo.
Methods We analysed the outcomes of death during treatment and relapse within 1 year of discharge for 288 patients treated 
with eflornithine, 311 patients treated with the standard melarsoprol regimen and 62 patients treated with a short-course (10-day) 
melarsoprol regimen between April 2001 and April 2005.
Findings A total of 1.7% (5/288) of patients treated with eflornithine died compared with 4.8% (15/311) of those treated with 
standard melarsoprol and 6.5% (4/62) of those treated with short-course melarsoprol. Patients treated with eflornithine tended to 
be younger and were more likely to have trypanosomes or higher white blood cell counts in their cerebrospinal fluid. The cumulated 
incidence of relapse among patients who attended at least one follow-up visit 1 year after discharge  was 8.1% (11/136) for those 
treated with eflornithine, 14% (36/258) for those treated with standard melarsoprol and 15.5% (9/58) for those treated with short-
course melarsoprol. In a multivariate analysis, when compared with eflornithine, standard melarsoprol was found to be a risk factor 
for both death (odds ratio (OR) = 2.87; 95% confidence interval (CI) = 1.03–8.00) and relapse (hazard ratio (HR) = 2.47; 95% CI = 
1.22–5.03); when compared with eflornithine, short-course melarsoprol was also found to be a risk factor for death (OR = 3.90; 
95% CI = 1.02–14.98) and relapse (HR = 6.65; 95% CI = 2.61–16.94).
Conclusion The effectiveness of melarsoprol treatment appears to have diminished. Eflornithine seems to be a better first-line 
therapy for treating late-stage Gambian trypanosomiasis in the Republic of the Congo.
Bulletin of the World Health Organization 2006;84:783-791.
Voir page 789 le résumé en français. En la página 790 figura un resumen en español.
Introduction
African trypanosomiasis is a public health 
hazard in many countries in sub-Saharan 
Africa, with an incidence of around 
20 000 new cases a year.1,2 The disease is 
fatal if untreated. Control programmes 
have been severely weakened by war 
and civil instability in many of the 
countries with the highest prevalence.3,4 
In central and west Africa the disease is 
predominantly caused by the protozoan 
Trypanosoma brucei gambiense and is 
transmitted by the tsetse fly (Glossina 
spp.) in a human–fly–human cycle. 
Pentamidine, first-line treatment for 
early-stage disease, cannot be used if 
the parasites have invaded the central 
nervous system because the drug does 
not cross the blood–brain barrier. The 
principal treatment options for late-stage 
(or stage-2) disease are either melarsoprol 
(an organoarsenic compound that in-
hibits parasite glycolysis) or eflornithine 
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(an irreversible inhibitor of ornithine 
decarboxylase which is necessary for 
the parasite’s synthesis of DNA and 
RNA). Both drugs must be adminis-
tered intravenously over a period of 1–4 
weeks, which is logistically challenging 
in health-care systems in the developing 
world. Melarsoprol is a highly toxic drug 
that causes encephalopathy in 5–10% of 
patients and approximately 40% of these 
patients will die.1,5 Eflornithine produces 
a reversible pancytopenia but otherwise 
appears to be safer than melarsoprol.6
Clinical research into new therapeu-
tic options for treating late-stage disease 
remains limited and is conducted by only 
a few national programmes, research 
institutions and nongovernmental or-
ganizations. Because it is unlikely that 
there will be any new molecules available 
in the next few years to treat late-stage 
disease, recent research has focused on 
optimizing the therapeutic regimens of 
the two registered drugs as well as on 
developing a combination treatment in-
volving a third drug, nifurtimox, which 
is unregistered to treat late-stage African 
trypanosomiasis but is available for 
compassionate use.4,7–12 The lack of new 
therapeutic options makes it crucial to 
monitor the use and effectiveness of the 
drug regimens currently being used.
Resistance to melarsoprol has been 
documented since the 1970s, but the 
majority of these reports come from 
east Africa.13,14 Health departments in 
countries in central and west Africa, in-
cluding Angola, Côte d’Ivoire and the 
Republic of the Congo, still recommend 
melarsoprol as first-line therapy for 
late-stage disease, although Angola has 
documented resistance to the drug.15
In the Republic of the Congo, fol-
lowing a period of civil war in the 1990s, 
Médecins Sans Frontières (MSF) assisted 
the Ministry of Health in implementing 
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Fig. 1. Flow of patients through the treatment programmes and data analysis
861 patients with
primary late-stage
Gambian
trypanosomiasis
Data from 661
analysed for risk factors
for death during treatment
637 survived treatment 24 died during treatment
185 excluded because discharged during
last year of the programme (insufficient follow-up time)
452 discharged up to
1 year before
programme ended
18 did not attend any follow-up visit
within first year after discharge
Data from 434
analysed for risk
factors for treatment
failure within first
year after discharge
378 cured 56 treatment failures
5 died before admission
103 enrolled in separate trial
16 treated with unorthodox regimens
76 with one or more missing variables
its national control programme for try-
panosomiasis. We present a retrospective 
analysis of the outcomes of patients 
with late-stage disease treated by this 
programme. Our analysis focuses on 
patients newly diagnosed with late-stage 
disease who were treated with one of 
the three first-line protocols used in the 
programme (eflornithine or the standard 
melarsoprol regimen or a 10-day short-
course melarsoprol regimen). The out-
comes assessed were death during treat-
ment and relapse within the first year 
after finishing treatment. We also inves-
tigated risk factors for both outcomes.
Methods
Diagnostic and treatment 
strategy
Between April 2001 and April 2005, the 
population of three separate historical 
foci of Gambian trypanosomiasis in 
the Republic of the Congo (Bouenza, 
Gamboma and Mossaka) were system-
atically screened by MSF in conjunction 
with the ministry of health’s control 
programme. Screening was performed 
using the card agglutination test for 
trypanosomes and physical examination 
for posterior cervical lymphadenopathy 
(Winterbottom’s sign). For patients who 
had a positive agglutination test a venous 
blood sample was examined for trypano-
somes using the Woo haematocrit centri-
fuge technique or quantitative buffy coat 
technique. Gambian trypanosomiasis 
was diagnosed if trypanosomes were seen 
in blood or lymph node samples, or if 
the agglutination test remained positive 
at a dilution of 1 in 8 or greater. All 
patients diagnosed with the disease had 
a cerebrospinal fluid sample taken by 
lumbar puncture; the sample was exam-
ined for trypanosomes and leukocytosis. 
The national protocol diagnosed central 
nervous system involvement (that is, 
late-stage disease) if trypanosomes were 
seen in the cerebrospinal fluid or if the 
white cell count in the cerebrospinal 
fluid was greater than 5 cells/mm³. From 
September 2002, following guidance 
from the ministry of health, MSF raised 
this threshold to 10 cells/mm³ in order 
to reduce the number of patients exposed 
to the risk of melarsoprol toxicity.16 This 
was accompanied by a formal change in 
the programme’s protocol in 2003.16,17
Both melarsoprol and eflornithine 
were available throughout the dura-
tion of the programme but melarsoprol 
remained the first-line therapy until 
August 2003; eflornithine was reserved 
for patients whom clinicians felt were 
too ill for melarsoprol. Internal analysis 
of the MSF programme results at this 
time led to eflornithine becoming the 
first-line therapy at all MSF sites as a 
result of a high case–fatality rate and 
relapse rate among patients treated 
with melarsoprol: 3/46 (6.5%) patients 
treated with eflornithine died or relapsed 
compared with 46/429 (10.7%) treated 
with melarsoprol. For the majority of 
patients melarsoprol was administered 
according to the standard regimen, al-
though the short-course 10-day regimen 
was used to treat a minority of patients 
(Fig. 1). Details of the various treatment 
regimens are given in Table 1.
For a patient’s data to be included 
in the study the patient had to have been 
diagnosed with late-stage disease using 
the standard national protocol algorithm, 
had to have had no previous treatment 
for the disease, and had to have been 
admitted to an MSF treatment centre 
between April 2001 and April 2005.
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Table 1. Treatments for late-stage Gambian trypanosomiasis used in the Republic 
of the Congo, April 2001–April 2005
Treatment Dose
Pre-treatment
Anti-malarial drugsa Artemisinin combination therapy
Anthelminthic drugsb Albendazole 400 mg to all patients
Anti-trypanosomal treatment
Standard melarsoprol regimen Day 1: 1.2 mg/kg IV c 
Day 2: 2.4 mg/kg IV 
Day 3–4: 3.6mg/kg IV
(Sequence repeats on days 12–15 and days 23–26)
Short-course melarsoprol regimen 2.2 mg/kg IV for 10 days
Eflornithine regimen 100–150mg/kg IV every 6 hours for 14 days
Additional treatment
Prednisoloned Day 1–4: 1mg/kg 
Day 12–15: 0.5mg/kg  
Day 23–26: 0.25mg/kge
a  Administered to febrile patients with positive thick-film or rapid test (Paracheck, Orchid, India).
b  Administered to all patients.
c  IV = intravenous.
d  Prednisolone administered to patients receiving melarsoprol.
e  Administered to patients being treated with the standard melarsoprol regimen.
Statistical analysis
Death during treatment
We investigated potential risk factors for 
death due to any cause during the first 
30 days after admission among patients 
with late-stage disease. We excluded 
from this analysis patients who were 
enrolled in an ongoing equivalence trial 
of eflornithine plus nifurtimox, had been 
treated with regimens other than me-
larsoprol (standard or short-course) or 
eflornithine, or for whom key baseline 
variables, such as age, sex, parasitological 
findings and treatment outcome, had not 
been reported.
First, we explored the univariate as-
sociations between death and potential 
risk factors (sex, age, screening mode 
— those cases identified by mobile 
teams in villages were denoted as active 
and those who self-presented at fixed 
screening posts were denoted as passive, 
technique on which parasitological 
confirmation was based, presence of 
trypanosomes in the cerebrospinal fluid, 
cerebrospinal fluid white cell count and 
drug regimen) and potential confound-
ers (site, project period — that is, before 
or after eflornithine was used as first-line 
treatment in August 2003) by calculat-
ing crude odds ratios (OR). We then fit 
a multivariate logistic regression model 
to adjust for the effects of confounding. 
Variables were entered into the model if 
they were associated with the outcome 
at the P < 0.20 level in the univariate 
analysis, and we gradually eliminated 
variables with nonsignificant multi-
variate associations (P > 0.05); we per-
formed likelihood ratio tests after each 
elimination, until we reached the final 
reduced model. We tested the model’s 
assumptions, including the correctness 
of specification and goodness of fit.
Relapse
To make best use of the data (consist-
ing of observations from patients with 
varying durations  of follow-up), we 
used survival analysis to investigate risk 
factors for treatment failure during the 
first year of follow-up. We computed 
univariate hazard ratios (HR) for failure 
as described in the section on “Death 
during treatment”, and then used Cox 
proportional hazards regression to adjust 
for confounders in a multivariate model. 
In addition to the exclusion criteria, we 
also excluded from this analysis all pa-
tients who were admitted less than 1 year 
before closure of the MSF programme or 
who did not attend at least one follow-up 
visit in the first year after discharge. We 
restricted our analysis to the first year 
of follow-up, since follow-up rates were 
unacceptably low for longer periods. 
We considered any visit after discharge 
occurring from month 10 (day 304) 
to month 14 (day 425) as a valid 1-year 
follow-up visit.
We defined relapse (or failure to 
have been cured at 1 year) as: death due 
to any cause after discharge, recurrence 
of parasites in any body fluid, white cell 
count in cerebrospinal fluid >50 cells/
mm³ and at least doubled from the pre-
vious measurement, or white cell count 
in cerebrospinal fluid 20–49 cells/mm³ 
with a significant increase from the pre-
vious measurement and/or symptoms 
suggestive of disease.
We calculated the person–time 
under observation as the time between 
discharge and treatment failure or loss 
to follow-up if these occurred before 
day 425 after discharge or the 1-year 
follow-up date for patients for whom 
treatment had not failed and who had 
not left before treatment was completed. 
The model was constructed as described 
in the previous section. We also tested 
for interactions among covariates and 
between covariates and time (propor-
tional hazards assumption).
Data collection and analysis
Personal, laboratory, treatment and out-
come data from source documents were 
entered into a Microsoft Excel database 
(in Gamboma) or YoTryps (in Bouenza 
and Mossaka), a Microsoft Access-based 
software program specifically designed 
for African trypanosomiasis programmes 
by MSF, at programme locations. Data 
were analysed using Stata software ver-
sion 8.0 (Stata Corp, College Station, 
Texas, USA).
Ethical approval
The study was a retrospective analysis of 
data from Médecins Sans Frontières’ op-
erational medical work in the Republic 
of the Congo. Approval for data exporta-
tion, analysis and reporting was obtained 
from the Ministry of Health’s national 
control programme in the Republic of 
the Congo. The datasets extracted and 
used for analysis were anonymized by 
removing all patients’ names, separating 
the data into a new dataset, and having 
the data analysed by a statistician uncon-
nected with the programmes.
Findings
Between April 2001 and April 2005, 
we treated 861 patients with late-stage 
disease; data on 661 (77%) met the 
inclusion criteria for analysis. Of these 
patients, 288 (44%) had been treated 
with eflornithine, 311 (47%) with the 
standard melarsoprol regimen and 62 
(9%) with short-course melarsoprol. 
An overall case–fatality rate of 3.6% 
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was found (24/661): 1.7% (5/288) of 
patients treated with eflornithine died 
compared with 4.8% (15/311) of those 
treated with the standard melarsoprol 
regimen and 6.5% (4/62) of those treated 
with short-course melarsoprol. Of the 
637 patients who survived and could be 
included in the analysis of relapse rate, 
452 (71%) were due for follow-up hav-
ing been treated more than 1 year before 
the programme ended. Of these, 434 
(96%) attended a follow-up visit within 
the first year. The cumulated incidence 
of relapse among those who attended 
at least one follow-up visit 1 year after 
Table 2. Baseline characteristics and outcomes of patients included in the analysis of treatments for late-stage Gambian 
trypanosomiasis, the Republic of the Congo, April 2001–April 2005
Patients Treatment regimena
Eflornithine Melarsoprol  
(standard)
Melarsoprol  
(short course)
Baseline characteristicsb
No. of patients 288 311 62
Treatment centre (province, town)
Gamboma (Gamboma town) 16 (5.6) 121 (38.9) 60 (96.8)
Bouenza (Nkayi town) 123 (42.7) 178 (57.2) 0 
Mossaka (Mossaka town) 149 (51.7) 12 (3.9) 2 (3.2)
Period of admission
Before August 2003 53 (18.4) 311 (100.0) 62 (100.0)
On/after August 2003 235 (81.6) 0 0 
No. (%) female 143 (49.7) 143 (46.0) 29 (46.8)
Age
> 15 years 217 (75.4) 259 (83.3) 60 (96.8)
< 15 years 71 (24.6) 52 (16.7) 2 (3.2)
Mode of screeningc
Active 169 (58.7) 197 (63.3) 41 (66.1)
Passive 119 (41.3) 114 (36.7) 21 (33.9)
Trypanosomes found in CSFd 157 (54.5) 99 (31.8) 7 (11.3)
White blood cell count in CSF (per µL)
0–19 85 (29.5) 127 (40.8) 34 (54.8)
20–99 74 (25.7) 74 (23.8) 16 (25.8)
> 100 129 (44.8) 110 (35.4) 12 (19.4)
Treatment outcomes
Died during treatment 5 (1.7) 15 (4.8) 4 (6.5)
Survived treatment 283 296 58
Survived treatment, discharged up to 1 year before project 
closure (data retained for further analysis)
136 258 58
Attended 6-month follow-up visit 94 (69.1) 206 (79.8) 18 (31.0)
Attended 1-year follow-up visit 70 (51.5) 156 (60.5) 12 (20.7)
Seen at least once during first year post-treatment 132 (97.1) 249 (96.5) 53 (91.4)
Median (interquartile range) person-days under observation 322 (202–366) 325 (184–365) 117 (45–290)
Treatment failed within first year (cumulated incidence assuming 
all patients lost to follow-up were cured)
11 (8.1) 36 (14.0) 9 (15.5)
a  See Table 1 for details of treatment regimens.
b  Values are number (percentage) unless otherwise indicated.
c  See text for a more detailed description of the mode of screening.
d  CSF = cerebrospinal fluid.
discharge was 8.1% (11/136) among 
those treated with eflornithine, 14% 
(36/258) among those treated with 
standard melarsoprol and 15.5% (9/58) 
among those treated with short-course 
melarsoprol.
The treatment groups differed sig-
nificantly (P < 0.001) in all baseline 
characteristics except for sex ratio and 
screening mode (Table 2). Patients 
treated with eflornithine were on aver-
age younger, were more likely to have 
trypanosomes in their cerebrospinal fluid 
and had higher white cell counts in their 
cerebrospinal fluid.
The case–fatality rate during treat-
ment was lower in the eflornithine 
group (P = 0.060). Follow-up rates and 
median person–time under observation 
were comparable between the eflorni-
thine group and the standard melar-
soprol group but significantly shorter 
(P < 0.001) in the short-course melarso-
prol group, in which only 20.7% (12/58) 
of patients attended the 1-year follow-up 
visit (Table 2). Among the 452 patients 
admitted more than 1 year before the 
programme ended and discharged alive, 
those who did not attend the 1-year 
follow-up visit differed significantly 
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(P < 0.001) from others in place of origin 
(47.2% (101/214) of those who did not 
attend follow-up versus 17.7% (42/238) 
of those who attended follow-up came 
from Gamboma), and were more likely 
to have white cell counts in cerebrospinal 
fluid >100 cells/mm³ (43.0% (92/214) 
versus 31.5% (75/238); P = 0.017). 
Furthermore, among all who did not 
complete follow-up (214), those in the 
eflornithine group were more likely to 
have parasites in their cerebrospinal fluid 
(51.5% (34/66) versus 29.7% (44/148); 
P = 0.002).
The cumulated incidence of relapse 
was nonsignificantly lower in the eflorni-
thine group (P = 0.084 for eflornithine 
versus standard melarsoprol regimen; 
P = 0.087 for eflornithine versus short-
course melarsoprol). No obvious cluster-
ing of relapses in time or by treatment 
centre was evident.
Multivariate analysis
The treatment centre, project period and 
diagnostic technique were weakly asso-
ciated with death among late-stage pa-
tients in the univariate analysis, but drug 
regimen emerged as the only significant 
risk factor in the final multivariate model 
(Table 3). Compared with patients re-
ceiving eflornithine, patients treated 
Table 3. Risk factors for death (n = 24) within 30 days after admission among patients with late-stage Gambian 
trypanosomiasis (n = 661) treated with melarsoprol or eflornithine, the Republic of the Congo, April 2001–April 2004
Baseline risk factor Crude odds ratioa Adjusted odds ratiob 
Treatment centre
Gamboma 1.00 –
Bouenza 1.15 (0.47–2.80)
Mossaka 0.29 (0.06–1.40)
Project period
Before August 2003 1.00 –
On/after August 2003 0.35 (0.12–1.04)
Sex
Male 1.00 –
Female 0.65 (0.28–1.50)
Age
> 15 years 1.00
< 15 years 0.60 (0.18–2.05)
Mode of screeningc 
Active 1.00 –
Passive 1.26 (0.56–2.81)
Technique on which parasitological confirmation was based
Direct gland puncture 1.00 –
Centrifuge technique (Woo or quantitative buffy coat) 0.40 (0.12–1.38)
CATTd dilution positive 0.45 (0.13–1.56)
Trypanosomes found in CSFe
No 1.00 –
Yes 0.75 (0.32–1.78)
White blood cell count in CSF (per µL)
0–19 1.00 –
20–99 1.73 (0.65–4.57)
> 100 0.85 (0.30–2.39)
Drug regimenf
Eflornithine 1.00 1.00
Melarsoprol (standard) 2.87 (1.03–8.00) 2.87 (1.03–8.00)
Melarsoprol (short course) 3.90 (1.02–14.98) 3.90 (1.02–14.98)
a  Values in parentheses are 95% confidence intervals.
b  Adjusted odds ratios based on logistic regression model with P = 0.05 (for goodness of fit).
c  See text for a more detailed description of the mode of screening.
d  CATT = card agglutination test for trypanosomes.
e  CSF = cerebrospinal fluid.
f  See Table 1 for details of treatment regimens.
with standard-regimen melarsoprol had 
an adjusted OR of dying of 2.87 (P = 
0.04), while those treated with short-
course melarsoprol had an adjusted OR 
of 3.90 (P = 0.05). Confidence intervals 
for these associations were wide, rang-
ing from almost no effect to an 8-fold 
increase in risk for standard melarsoprol 
and a 15-fold increase for short-course 
melarsoprol.
Baseline cerebrospinal fluid white 
cell counts and drug regimen were the 
only significant risk factors for relapse 
among patients with late-stage disease 
within 1 year after discharge in both 
the univariate and multivariate analyses 
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(Table 4). Both a high white cell count 
in cerebrospinal fluid and melarsoprol 
therapy (compared with eflornithine) 
increased the risk of relapse. When the 
project period was retained in the final 
model, it had a nonsignificant effect (ad-
justed HR = 0.91; 95% CI = 0.26–3.13), 
but it appeared to influence marginally 
the effect of treatment, yielding an ad-
justed HR for treatment failure of 2.35 
(95% CI = 0.85–6.53; P = 0.101) for 
patients treated with standard melarso-
prol and 6.32 (95% CI = 1.90–20.97; 
P = 0.003) for patients receiving short-
course melarsoprol.
Discussion
When compared with eflornithine both 
regimens of melarsoprol were associ-
ated with higher mortality and a higher 
cumulated incidence of relapse among 
patients treated for late-stage Gambian 
trypanosomiasis. Our data confirm the 
general consensus that eflornithine is 
safer than melarsoprol, even when used 
in routine practice. The cumulated 
incidences of relapse, though likely to 
be underestimated, were unacceptably 
high for both melarsoprol regimens. 
In particular the short-course regimen 
performed particularly poorly. Given a 
treatment failure rate of around 14%, 
we believe that resistance to melarsop-
rol therapy is a considerable obstacle to 
the control of sleeping sickness in the 
Republic of the Congo.
Our data have certain limitations. 
The non-randomized nature of our 
study makes it difficult to truly com-
pare treatments, even when differences, 
such as age, presence of parasites and 
cerebrospinal fluid white cell counts, 
are adjusted for. Moreover, data were 
retrospective and collected from an op-
erational programme not a research pro-
gramme. However, there are significant 
challenges involved in implementing 
and conducting randomized controlled 
trials of treatment for this disease. Thus 
there is a scarcity of published data on 
the use of melarsoprol and eflornithine 
outside routine care, and there has been 
only one study published that directly 
compares the two drugs (melarsoprol 
and eflornithine).12 We therefore be-
lieve this makes our study relevant and 
worthwhile.
Another limitation of our study is 
the generally low rate of follow-up. Our 
rates are similar to those of other studies, 
reflecting the real difficulty of tracing pa-
tients in resource-poor environments.9–12 
Table 4. Risk factors for treatment failure within the first year after discharge 
(n = 56) among 434 patients with late-stage Gambian trypanosomiasis 
treated with melarsoprol or eflornithine, the Republic of the Congo, April 
2001–April 2004
Baseline risk factor Crude hazard ratioa Adjusted hazard 
ratiob
Treatment centre
Gamboma 1.00 –
Bouenza 0.89 (0.48–1.68)
Mossaka 0.56 (0.23–1.35)
Project period
Before August 2003 1.00 –
On/after August 2003 0.39 (0.17–0.92)
Sex
Male 1.00 –
Female 0.81 (0.48–1.38)
Age
> 15 years 1.00 –
> 15 years 0.80 (0.41–1.56)
Mode of screeningc 
Active 1.00 –
Passive 1.42 (0.84–2.40)
Technique on which parasitological 
confirmation was based
Direct gland puncture 1.00 –
Centrifuge technique (Woo or 
quantitative buffy coat)
1.25 (0.67–2.32)
CATTd dilution positive 1.43 (0.72–2.83)
Trypanosomes found in CSFe
No 1.00 –
Yes 1.21 (0.71–2.06)
White blood cell count in CSF (per µL)
0–19 1.00 1.00
20–99 1.57 (0.71–3.55) 1.99 (0.88–4.50)
> 100 3.09 (1.56–6.15) 3.95 (1.96–7.96)
Drug regimen f
Eflornithine 1.00 1.00
Melarsoprol (standard) 2.16 (1.05–4.44) 2.47 (1.22–5.03)
Melarsoprol (short course) 4.66 (1.85–11.77) 6.65 (2.61–16.94)
a  Values in parentheses are 95% confidence intervals.
b  Adjusted hazard ratios based on Cox regression model with P < 0.001 (for goodness of fit).
c  See text for a more detailed description of the mode of screening.
d  CATT = card agglutination test for trypanosomes.
e  CSF = cerebrospinal fluid.
f  See Table 1 for details of treatment regimens.
However, follow-up rates for patients 
treated with the standard melarsoprol 
regimen and with eflornithine were 
similar, allowing us to compare the two. 
It is difficult to predict the implications 
of loss to follow-up, but it seems prob-
lematic to assume that all those who 
were lost were actually cured. This would 
imply that all patients who relapsed were 
followed-up, so it inevitably leads to an 
underestimate of the true rate of relapse. 
It is possible that many patients who 
relapsed may not have wished to return 
for follow-up. Additionally, deaths that 
resulted from relapses may also have 
been included in the category of those 
who were lost to follow-up. Also, our 
follow-up was limited to the first year 
after treatment.
The deliberate decision to change 
the treatment protocol in our programme 
is a potential source of bias. However, the 
baseline characteristics of the two groups 
would tend to favour a better outcome 
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for those patients treated with melarso-
prol. Patients treated with eflornithine 
tended to have more risk factors for a 
poor prognosis such as higher white cell 
count and/or parasitaemia in cerebro-
spinal fluid. This bears out anecdotal re-
ports from the field that when the choice 
is available, clinicians are reluctant to use 
melarsoprol for those patients who are 
the most unwell. Despite a better base-
line profile, the risk of death and relapse 
was greater in the melarsoprol group.
Even with these limitations our 
data still provide useful information 
on the only drugs available for treating 
late-stage disease. A literature search 
identified several prospective studies 
of each treatment that reported 2-year 
cure rates of 97% for eflornithine and 
86–95% for melarsoprol.8–12,18 How-
ever, there is only one large published 
retrospective non-randomized com-
parison of these two drugs. Chappuis 
et al. showed that eflornithine was safer 
and caused fewer deaths and adverse 
events during treatment.12 However, no 
statistical difference was seen at 1-year 
post-treatment, and the follow-up rate 
at 1 year was 46%.
Apart from melarsoprol’s higher tox-
icity, the higher cumulated incidence of 
relapse found in our study would in itself 
justify reconsidering its use as first-line 
therapy for late-stage Gambian trypano-
somiasis in the Republic of the Congo. 
However, this analysis is important for 
two other reasons. First, little data has 
been published in support of the new 
short-course melarsoprol regimen.9–11 
This new regimen has been justified on 
the basis of its superiority in terms of 
clinical implementation rather than of 
efficacy. The risk of relapse due to drug 
resistance is therefore likely to be no 
better with short-course melarsoprol. 
Indeed, in our small cohort, relapse levels 
were similar when the short-course was 
compared with the standard regimen. 
Short-course melarsoprol is therefore 
unlikely to solve the problem of the 
high relapse rate in the Republic of the 
Congo.
Second, Pepin and Mpia have re-
ported in a longitudinal study that they 
found no evidence of a change in me-
larsoprol resistance over 20 years.18 This 
would seem to offer some reassurance to 
those who continue to use melarsoprol. 
However, the authors made no direct 
comparison between melarsoprol and 
eflornithine, and hence this result must 
be viewed with some caution.
Because melarsoprol has low cure 
rates at 1 year, it appears that eflornithine 
is the better treatment option for new 
cases of late-stage disease. It has often 
been argued that eflornithine is difficult 
to administer in resource-poor settings 
because patients require a higher level 
of nursing care. Additional costs related 
to eflornithine administration (for drip 
sets, saline infusions, intravenous cath-
eters) are also seen as another hurdle to 
its widespread use. While it is true that 
infusions have to be prepared every 6 
hours, it is our experience that the tech-
nical level of nursing care required has 
been overestimated. The main priorities 
in administering eflornithine are to 
ensure that all infusions are prepared 
and given regularly in a sterile man-
ner.12 However, patients on eflornithine 
experience far fewer adverse events than 
those on melarsoprol; thus the level of 
nursing care required beyond the prepa-
ration and administration of infusions is 
considerably less than with melarsoprol 
treatment, during which patients who 
experience encephalopathy reactions 
require intensive nursing care. Hence, 
the presence of 24-hour nursing care to 
provide night infusions is probably the 
more important factor that keeps eflo-
rnithine from being used more widely. 
We therefore recommend eflornithine 
for first-line treatment of the disease 
in the Republic of the Congo. We also 
recommend that the additional materials 
(including saline infusions, drip sets and 
intravenous catheters) required for the 
administration of eflornithine should 
be provided free as part of the current 
eflornithine donation project under 
which the drugs are provided free by 
manufacturers to WHO to be distrib-
uted to affected countries.
Future research into the treatment of 
African trypanosomiasis should look at 
combination treatments to improve the 
efficacy of treatment and delay the devel-
opment of resistance to eflornithine. A 
trial of nifurtimox plus eflornithine com-
bination therapy has been undertaken in 
our centres in the Republic of the Congo 
(comparing eflornithine 100mg/kg ad-
ministered intravenously 4 times a day 
for 14 days versus eflornithine 200mg/kg 
administered intravenously 2 times a day 
for 7 days plus nifurtimox 15mg/kg a 
day divided in 3 doses for 10 days). Data 
from the study will be published in the 
future (U Karunakara and G Priotto, 
personal communication, 2005). Further 
trials examining this combination treat-
ment are being undertaken at other study 
sites. This combination offers the advan-
tage of limiting eflornithine infusions to 
twice a day. We believe this would be an 
excellent regimen if safety and efficacy 
can be demonstrated. It will be a useful 
interim regimen until new molecules are 
developed and available for use.
Conclusion
In the Republic of the Congo, the ef-
fectiveness of melarsoprol is insufficient 
to justify its continued use as first-line 
treatment. We recommend administer-
ing a 14-day course of eflornithine as 
first-line treatment until better treatment 
regimens are available.  O
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Résumé
Évaluation comparative du mélarsoprol et de l’éflornithine dans le traitement de la trypanosomiase à 
Tr. brucei Gambiense à un stade avancé en République du Congo
Objectif Comparer l’efficacité du mélarsoprol et de l’éflornithine 
dans le traitement de la trypanosomiase à Tr. brucei Gambiense à 
un stade avancé en République du Congo.
Méthodes Nous avons analysé les cas de décès pendant le 
traitement ou à l’occasion d’une rechute dans l’année suivant la 
sortie du traitement parmi 288 individus traités par l’éflornithine, 
311 individus soumis à un traitement standard par le mélarsoprol 
et 62 autres recevant ou ayant reçu une cure brève de mélarsoprol 
(10 jours), sur la période allant d’avril 2001 à avril 2005.
Résultats Au total, 1,7 % (5/288) des sujets traités par 
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Resumen
Comparación del melarsoprol y la eflornitina como tratamiento de la fase tardía de la tripanosomiasis 
gambiense en la República del Congo
Objetivo Comparar la eficacia del melarsoprol y de la eflornitina 
como tratamiento de la fase tardía de la tripanosomiasis gambiense 
en la República del Congo.
Métodos Analizamos los casos de defunción durante el 
tratamiento y de recaída durante el primer año tras el alta en 
288 pacientes tratados con eflornitina, 311 sometidos al régimen 
estándar de melarsoprol y 62 sometidos al tratamiento de corta 
duración (10 días) con melarsoprol entre abril de 2001 y abril de 
2005.
Resultados En total murieron el 1,7% (5/288) de los pacientes 
tratados con eflornitina, frente al 4,8% (15/311) de los sometidos 
al tratamiento estándar de melarsoprol y el 6,5% (4/62) de 
los tratados con el régimen de corta duración de melarsoprol. 
Los pacientes tratados con eflornitina solían ser más jóvenes y 
tenían más probabilidades de albergar tripanosomas o un mayor 
número de leucocitos en el líquido cefalorraquídeo. La incidencia 
acumulada de recaídas entre los pacientes que acudieron al menos 
a una visita de seguimiento al cabo de un año del alta fue del 
8,1% (11/136) para los tratados con eflornitina, 14% (36/258) 
para los tratados con el régimen estándar de melarsoprol, y 15,5% 
(9/58) para los sometidos al tratamiento de corta duración con 
melarsoprol. En el análisis multifactorial realizado, al compararlo 
con la eflornitina, el régimen estándar de melarsoprol resultó ser un 
factor de riesgo tanto de defunción (razón de posibilidades (OR) = 
2,87; intervalo de confianza (IC) del 95% = 1,03-8,00) como de 
recaída (razón instantánea de riesgos (RIR) = 2,47; IC95%  = 
1,22–5,03); en comparación con la eflornitina, el tratamiento de 
corta duración con melarsoprol también fue un factor de riesgo 
de defunción (OR = 3,90; IC95%  = 1,02–14,98) y de recaídas 
(RIR = 6,65; IC95%  = 2,61–16,94).
Conclusiones La eficacia del melarsoprol ha disminuido. La 
eflornitina parece una terapia de primera línea preferible para tratar 
la fase tardía de la tripanosomiasis gambiense en la República 
del Congo.
صخلم
وغنوكلا ةيروهمج في ةرخأتلما هتلحرم في ةيبماغلا تايبقثلما ءاد ةجلاعم في ينثينرولفيلإا لباقم لوربوسرلايلما
 ةجلاعم  في  ينثينرولفيلإا  ةيلاّعفو  لوربوسرلايلما  ةيلاّعف  ينب  ةنراقم  :فدهلا
.وغنوكلا ةيروهمج في تايبقثلما ءاد نم ةمدقتلما لحارلما
 ةنس  ةرـتف  للاخ  سكنلاو  ةجلاعلما  ءانثأ  تايفولا  لئاصح  انلّلح  :ةقيرطلا
 ةجلاعم اوجلوع ًاضيرم 311و ،ينثينرولفيلإاب اوجلوع ًاضيرم 288 جرخت نم
 يرصق يجلاع ماظنب  اوجلوع  ًاضيرم  62  بناج لىإ  ،لوربوسرلايلماب  ةيرايعم
/ناسينو 2001 ليربإ/ناسين ينب ةرـتفلا في ،لوربوسرلايلماب )مايأ 10( دملأا
.2005 ليربإ
 ينثينرولفيلإاب اوجلوع نّمـم )ًاضيرم 288 ينب نم 5( %1.7 تام :تادوجولما
 ةجلاعلما  ماظنب  اوجلوع  نّمـم  )ًاضيرم  311  ينب  نم  15(  %4.8  ـب  ًةنراقم
 اوجلوع  نّمـم  )ًاضيرم  62  ينب  نم  4(  %6.5و  ،لوربوسرلايلماب  ةيرايعلما
 ينثينرولفيلإاب ينَجلاعلما لييمو .لوربوسرلايلماب دملأا ةيرصقلا ةجلاعلما ماظنب
 عافترا  وأ  مهيدل  تايبقثلما  دوجو لماتحا  ديازت  عم  ًارمع رغصأ اونوكي  نلأ
 عوقولا  لدعم  غلب  دقو  .مهيدل  يعاخنلا  لئاسلا  في  ضيبلا  تايركلا  دادعت
 ةعباتملل لقلأا لىع ةدحاو ةرلم اوعجار نيذلا ضىرلما ىدل سكنلل يمكاترلا
 ينب نم )ًاضيرم 136  لصأ نم 11( %8.1  مهجيرخت لىع ةنس رورم دعب
 ينَجلاعلما  نم  )ًاضيرم  258  ينب  نم  36(  %14و  ،ينثينرولفيلإاب  ينَجلاعلما
 )ًاضيرم  58  ينب  نم  9(  %15.5و  ،لوربوسرلايلماب  ةيرايعم  ةجلاعم  ماظنب
 د ِّدعتلما ليلحتلا فيو .لوربوسرلايلماب دملأا يرصق يجلاع ماظنب اوجلوع نّمم
 عم  لوربوسرلايلماب  يرايعلما  يجلاعلا  ماظنلا  ةنراقم  ىدل  اندجو  تايرغتلما
 لكشي  لوربوسرلايلماب  يرايعلما  يجلاعلا  ماظنلا  نأ  ينثينرولفيلإاب  ةجلاعلما
 ذإ  ،%95  ةقث  ةلصافبو ،2.87  ةيحجرأ  ةبسنب(  توملل  رطخلا  لماوع دحأ
 2.47 ةيحجرأ ةبسنب( سكنللو )8.00و 1.03 ينب ةيحجرلأا بسن تحوارت
 ناك ماك .)5.03و 1.22 ينب ةيحجرلأا بسن تحوارت ذإ %95 ةقث ةلصافبو
 نم ينثينرولفيلإاب هتنراقم ىدل لوربوسرلايلماب دملأا ةيرصقلا ةجلاعلما ماظن
 تحوارت ذإ %95 ةقث ةلصافبو 3.90 ةيحجرأ ةبسنب( توملل رطخلا لماوع
 ةلصافبو 6.65 ةيحجرأ ةبسنب( سكنللو )14.98و 1.02 ينب ةيحجرلأا بسن
.)16.94و 2.61 ينب ةيحجرلأا بسن تحوارت ذإ %95 ةقث
 نأ  ودبيو ،تصقانت  دق لوربوسرلايلماب  ةجلاعلما  ةيلاّعف  نأ  ودبي  :جاتنتسلاا
 ءاد  نم  ةم ِّدقتلما  لحارلما  ةجلاعلم  لولأا  طخلا  في  هنم  لضفأ  ينثينرولفيلإا
.ةيطارقيمدلا وغنوكلا ةيروهمج في ةيبماغلا تايبقثلما
l’éflornithine sont morts contre 4,8 % (15/311) de ceux soumis 
à traitement standard par le mélarsoprol et 6,5 % (4/62) de 
ceux traités par une cure brève de mélarsoprol. Les sujets traités 
par l’éflornithine tendaient statistiquement à être plus jeunes et 
présentaient une plus grande probabilité d’avoir des trypanosomes 
ou une numération leucocytaire plus élevée dans le liquide 
céphalorachidien. L’incidence cumulée des rechutes parmi les sujets 
s’étant présentés à une visite de suivi au moins après leur sortie 
du traitement était de 8,1 % (11/136) pour les sujets traités par 
l’éflornithine, de 14 % (36/258) pour ceux ayant reçu un traitement 
standard par le mélarsoprol et de 15,5 % (9/58) pour ceux soumis 
à une cure brève de ce médicament. Une analyse multivariée a 
fait apparaître le traitement standard par le mélarsoprol comme 
facteur de risque par rapport au traitement par l’éflornithine à la 
fois pour le décès [odds ratio (OR) = 2,87; IC à 95 % = 1,03 - 8,00 
et la rechute (ratio de danger = 2,47; IC à 95 % = 1,22 - 5,03). La 
cure brève par le mélarsoprol s’est également révélée un facteur 
de risque par rapport au traitement par l’éflornithine pour le décès 
(OR = 3,90; IC à 95 % = 1,02 - 14,98) et la rechute (ratio de 
danger = 6,65; IC à 95 % = 2,61 - 16,94).
Conclusion Il semble que l’efficacité du traitement par le 
mélarsoprol ait diminué. L’éflornithine semble mieux convenir 
comme traitement de première intention face à la trypanosomiase 
«gambienne» à un stade avancé en République du Congo.
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